IMAC Holdings to acquire Theralink in reverse merger; Theralink shareholders to own 85%

IMAC Holdings, Inc.

Stock-for-stock reverse merger: Theralink survives as wholly owned subsidiary of IMAC (BACK).
Theralink stakeholders expected to own ~85% of combined company; pre-merger IMAC holders ~15%.
Merger expected to close late Q3 or early Q4 2023, subject to shareholder and regulatory approvals.
All current IMAC directors except one to resign at close; Theralink directors appointed, Jeffrey Busch as Chairman.
Combined company to focus on Theralink's proteomics cancer testing platform.

item 1.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

IMAC Holdings, Inc. entered into Agreement and Plan of Merger with Theralink Technologies, Inc. (effective 2023-05-23).

Action: entry
Agreement: merger
Counterparty: Theralink Technologies, Inc.
Effective: 2023-05-23

Exact text from the filing

On May 23, 2023, IMAC Holdings, Inc., a Delaware corporation (Nasdaq: BACK) (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Theralink Technologies, Inc. (OTC: THER), a Nevada corporation (“Theralink”), and IMAC Merger Sub, Inc., a Delaware corporation and a newly formed, wholly owned subsidiary of the Company (“Merger Sub”).

View on SEC.gov

269 material agreements filed in the last 30 days. Browse all material agreements →

IMAC Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-019327

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.